GLP-1 Drugs May Play Modest Role in Cancer Prevention

In two observational studies that included more than 170,000 and 86,000 patients, respectively, with obesity and/or diabetes, researchers found that glucagon-like–peptide (GLP)-1 receptor agonists may lead to modest declines in the development of more than a dozen types of obesity-related cancer, such as colorectal cancer. The findings should reassure clinicians who prescribe the medicines yet may wonder about a connection to cancer based on early studies of the drugs.